[go: up one dir, main page]

ECSP044974A - Formulación de suspensión oral estabilizada - Google Patents

Formulación de suspensión oral estabilizada

Info

Publication number
ECSP044974A
ECSP044974A EC2004004974A ECSP044974A ECSP044974A EC SP044974 A ECSP044974 A EC SP044974A EC 2004004974 A EC2004004974 A EC 2004004974A EC SP044974 A ECSP044974 A EC SP044974A EC SP044974 A ECSP044974 A EC SP044974A
Authority
EC
Ecuador
Prior art keywords
formulation
oral suspension
stabilized oral
thixotropic
agent
Prior art date
Application number
EC2004004974A
Other languages
English (en)
Inventor
Guang Wei Lu
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of ECSP044974A publication Critical patent/ECSP044974A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dental Preparations (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proveen composiciones farmacéuticas para administrar en forma oral que comprenden una droga de baja solubilidad en agua suspendida en un vehículo líquido acuoso que comprende un agente humectante, un agente espesante tixotrópico, y un agente de suspensión inorgánico. Las composiciones son tixotrópicas, sustancialmente desfloculadas y físicamente son estables de manera sustancial.
EC2004004974A 2001-08-06 2004-02-06 Formulación de suspensión oral estabilizada ECSP044974A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31037201P 2001-08-06 2001-08-06

Publications (1)

Publication Number Publication Date
ECSP044974A true ECSP044974A (es) 2004-03-23

Family

ID=23202195

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004004974A ECSP044974A (es) 2001-08-06 2004-02-06 Formulación de suspensión oral estabilizada

Country Status (34)

Country Link
US (2) US20030108575A1 (es)
EP (1) EP1414409B1 (es)
JP (1) JP2005500363A (es)
KR (1) KR20040025740A (es)
CN (1) CN1287768C (es)
AP (1) AP1817A (es)
AT (1) ATE353627T1 (es)
BR (1) BR0211736A (es)
CA (1) CA2454173A1 (es)
CO (1) CO5560559A2 (es)
CY (1) CY1106548T1 (es)
DE (1) DE60218175T2 (es)
DK (1) DK1414409T3 (es)
EA (1) EA007901B1 (es)
EC (1) ECSP044974A (es)
ES (1) ES2280560T3 (es)
GE (1) GEP20074027B (es)
HK (1) HK1069542A1 (es)
HR (1) HRP20040118A2 (es)
IL (1) IL159551A0 (es)
IS (1) IS7126A (es)
MA (1) MA27054A1 (es)
MX (1) MXPA04001109A (es)
MY (1) MY135119A (es)
NZ (1) NZ530844A (es)
OA (1) OA12646A (es)
PL (1) PL366382A1 (es)
PT (1) PT1414409E (es)
SI (1) SI1414409T1 (es)
TN (1) TNSN04023A1 (es)
UA (1) UA80682C2 (es)
WO (1) WO2003013473A1 (es)
YU (1) YU7404A (es)
ZA (1) ZA200400639B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720061D0 (en) 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
US9101540B2 (en) * 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US20050036956A1 (en) * 2003-08-15 2005-02-17 Lin Fei Non-aqueous liquid tooth whitening composition
TR200301552A1 (tr) * 2003-09-18 2005-10-21 Nobel İlaç Sanayi̇ Ve Ti̇caret A. Ş. Rofekoksib' in yeni oral farmakolojik formülasyonları.
US20050266031A1 (en) * 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
US8318210B2 (en) * 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
US8653145B2 (en) * 2005-09-22 2014-02-18 Eaton Scientific Systems, Ltd. Method for alleviating climacteric symptoms
MY157620A (en) 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
WO2007125339A1 (en) 2006-04-26 2007-11-08 Rosemont Pharmaceuticals Ltd Liquid oral compositions
CN100434072C (zh) * 2006-06-19 2008-11-19 西安交通大学 具有抗炎性作用及改善血液流变性和抑制血栓形成的药物
GB0714670D0 (en) 2007-07-27 2007-09-05 Ineos Healthcare Ltd Use
GB0720220D0 (en) 2007-10-16 2007-11-28 Ineos Healthcare Ltd Compound
WO2009133431A1 (en) * 2008-04-30 2009-11-05 Wockhardt Research Centre Oral liquid compositions of rhein or diacerein
GB0913525D0 (en) 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
GB201001779D0 (en) 2010-02-04 2010-03-24 Ineos Healthcare Ltd Composition
WO2011107855A2 (en) 2010-03-04 2011-09-09 Torrent Pharmaceuticals Limited Sustained release oral liquid suspension dosage form
PT2544532T (pt) 2010-03-12 2017-06-02 Monsanto Technology Llc Composições de gel agroquímicas
ES2690257T3 (es) * 2010-06-02 2018-11-20 Astellas Deutschland Gmbh Formas de dosificación oral de bendamustina
EP2462922A1 (en) * 2010-12-10 2012-06-13 Bioprojet New form of administration of enkephalinase inhibitor
KR102075173B1 (ko) * 2011-01-18 2020-02-07 센주 세이야꾸 가부시키가이샤 보존 효력을 갖는 브롬페낙 수성 액제 조성물
WO2014078435A1 (en) 2012-11-14 2014-05-22 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide
EP3302430A4 (en) * 2015-05-29 2019-05-29 codaDose Incorporated Liquid Formulations of Celecoxib for Oral Administration
US11083780B2 (en) 2015-07-20 2021-08-10 The Brigham And Women's Hospital, Inc. Shear-thinning compositions as an intravascular embolic agent
CN105902409B (zh) * 2016-05-13 2019-03-05 广东龙湖科技股份有限公司 一种温和且具有触变性的牙膏
AU2017345473A1 (en) * 2016-10-19 2019-04-18 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
WO2019070818A2 (en) * 2017-10-04 2019-04-11 Panacea Biomatx, Inc. SUSPENSION OF ENCAPSULATED PHARMACEUTICAL PRODUCTS AND METHODS OF MAKING AND USING SAME
CN112402376A (zh) * 2019-08-22 2021-02-26 上海上药信谊药厂有限公司 一种结肠靶向的柳氮磺吡啶口服混悬剂及其制备方法
CN114931552A (zh) * 2021-02-12 2022-08-23 浙江贝灵生物医药有限公司 一种口服碱性溶媒组合物及其制备方法与应用
WO2022185338A1 (en) * 2021-03-05 2022-09-09 Alkem Laboratories Limited Stable oral suspension of celecoxib and method of preparation thereof
KR20240161261A (ko) 2023-05-04 2024-11-12 주식회사 퍼슨 성상 안정성이 우수한 현탁액 조성물

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684666A (en) * 1986-08-19 1987-08-04 Haas Pharmaceuticals, Inc. Stabilized liquid analgesic compositions
WO1991008734A1 (en) * 1989-06-13 1991-06-27 Abbott Laboratories Anhydrous oil-based liquid suspension for delivering a medicament
US5112604A (en) * 1989-09-01 1992-05-12 Riker Laboratories, Inc. Oral suspension formulation
US5616458A (en) * 1990-03-14 1997-04-01 Board Of Regents, University Of Tx System Tripterygium wilfordii hook F extracts and components, and uses thereof
US5604260A (en) * 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5543297A (en) * 1992-12-22 1996-08-06 Merck Frosst Canada, Inc. Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
US5380738A (en) * 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5344991A (en) * 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5401765A (en) * 1993-11-30 1995-03-28 G. D. Searle 1,4,5-triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders
US5434178A (en) * 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
US5475018A (en) * 1993-11-30 1995-12-12 G. D. Searle & Co. 1,5-diphenyl pyrazole compounds for treatment of inflammation
NZ276885A (en) * 1993-11-30 1999-08-30 Searle & Co Substituted pyrazolyl-benzenesulphonamide derivatives, preparation and pharmaceutical compositions thereof
US5393790A (en) * 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
WO1995030652A1 (en) * 1994-05-04 1995-11-16 G.D. Searle & Co. Substituted spirodienes for the treatment of inflammation
US5418254A (en) * 1994-05-04 1995-05-23 G. D. Searle & Co. Substituted cyclopentadienyl compounds for the treatment of inflammation
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
JPH10504542A (ja) * 1994-07-27 1998-05-06 ジー．ディー．サール アンド カンパニー 炎症処置用の置換チアゾール化合物
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5521213A (en) * 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5420343A (en) * 1994-08-31 1995-05-30 G. D. Searle & Co. Derivatives of aromatic cyclic alkylethers
US5585504A (en) * 1994-09-16 1996-12-17 Merck & Co., Inc. Process of making cox-2 inhibitors having a lactone bridge
US5696143A (en) * 1994-09-20 1997-12-09 Talley; John J. Benz G! indazolyl derivatives for the treatment of inflammation
US5547975A (en) * 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
US5849943A (en) * 1994-10-27 1998-12-15 Merck Frosst Canada, Inc. Stilbene derivatives useful as cyclooxygenase-2 inhibitors
US5739166A (en) * 1994-11-29 1998-04-14 G.D. Searle & Co. Substituted terphenyl compounds for the treatment of inflammation
JP3181190B2 (ja) * 1994-12-20 2001-07-03 日本たばこ産業株式会社 オキサゾール誘導体
JP2636819B2 (ja) * 1994-12-20 1997-07-30 日本たばこ産業株式会社 オキサゾール系複素環式芳香族化合物
US5552422A (en) * 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
CA2211320C (en) * 1995-01-31 2007-03-20 Merck Frosst Canada Inc. 5-methanesulfonamido-3h-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2
US5686470A (en) * 1995-02-10 1997-11-11 Weier; Richard M. 2, 3-substituted pyridines for the treatment of inflammation
US5596008A (en) * 1995-02-10 1997-01-21 G. D. Searle & Co. 3,4-Diaryl substituted pyridines for the treatment of inflammation
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US5510368A (en) * 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5604253A (en) * 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5639780A (en) * 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
ES2182991T3 (es) * 1995-05-25 2003-03-16 Searle & Co Metodo para la preparar 3-haloalquil-1h-pirazoles.
US5643933A (en) * 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
IL118544A (en) * 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
GB9514518D0 (en) * 1995-07-15 1995-09-13 Sod Conseils Rech Applic Guanidine salt inhibitors of NO synthase and cyclooxygenase
JPH0977664A (ja) * 1995-09-13 1997-03-25 Yakult Honsha Co Ltd シクロオキシゲナーゼ−２特異的阻害剤及び抗炎症剤
US5756529A (en) * 1995-09-29 1998-05-26 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
US5981576A (en) * 1995-10-13 1999-11-09 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
US6020343A (en) * 1995-10-13 2000-02-01 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
US6057319A (en) * 1995-10-30 2000-05-02 Merck Frosst Canada & Co. 3,4-Diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors
PL187516B1 (pl) * 1996-01-11 2004-07-30 Smithkline Beecham Corp Nowe podstawione pochodne imidazolu, sposób ich wytwarzania oraz kompozycja farmaceutyczna zawierająca te związki
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
US5789413A (en) * 1996-02-01 1998-08-04 Merck Frosst Canada, Inc. Alkylated styrenes as prodrugs to COX-2 inhibitors
GB9607503D0 (en) * 1996-04-11 1996-06-12 Merck Frosst Canada Inc Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors
US5807873A (en) * 1996-04-04 1998-09-15 Laboratories Upsa Diarylmethylidenefuran derivatives and their uses in therapeutics
ES2311571T3 (es) * 1996-04-12 2009-02-16 G.D. Searle Llc Derivados de bencenosulfonamida sustituidos como profarmacos de inhibidores de cox-2.
US5922742A (en) * 1996-04-23 1999-07-13 Merck Frosst Canada Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors
US5883267A (en) * 1996-05-31 1999-03-16 Merck & Co., Inc. Process for making phenyl heterocycles useful as cox-2 inhibitors
US5741798A (en) * 1996-06-03 1998-04-21 Boehringer Ingelheim Pharmaceuticals, Inc. 2-benzyl-4-sulfonyl-4H-isoquinolin-1,3-diones and their use as antiinflammatory agents
US5677318A (en) * 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
US5776967A (en) * 1996-07-26 1998-07-07 American Home Products Corporation Pyranoindole inhibitors of COX--2
FR2751964B1 (fr) * 1996-08-01 1998-10-30 Union Pharma Scient Appl Nouveaux derives diarylmethylene carbocycliques, leurs procedes de preparation, et leurs utilisations en therapeutique
FR2751966B1 (fr) * 1996-08-01 1998-10-30 Union Pharma Scient Appl Nouveaux derives 1,2-diarylindoles, leurs procedes de preparation, et leurs utilisations en therapeutique
US5830911A (en) * 1996-08-14 1998-11-03 American Home Products Corporation Pyranoindole and tetrahydrocarbazole inhibitors of COX-2
US6005000A (en) * 1996-08-22 1999-12-21 Oxis International, Inc. 5,5-Disubstituted-3, 4-dihydroxy-2(5H)-furanones and methods of use therefor
FR2753449B1 (fr) * 1996-09-13 1998-12-04 Union Pharma Scient Appl Nouveaux derives 3,4-diaryloxazolone, leurs procedes de preparation, et leurs utilisations en therapeutique
US5972950A (en) * 1996-10-08 1999-10-26 Laboratories Upsa 1,2-diarylmethylene derivatives, their methods of preparation and their uses in therapeutics
US5681842A (en) * 1996-11-08 1997-10-28 Abbott Laboratories Prostaglandin synthase-2 inhibitors
US5869524A (en) * 1996-11-12 1999-02-09 American Home Products Corporation Indene inhibitors of COX-2
US6096753A (en) * 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
WO1998025896A1 (en) * 1996-12-10 1998-06-18 G.D. Searle & Co. Substituted pyrrolyl compounds for the treatment of inflammation
US5973191A (en) * 1996-12-30 1999-10-26 Vanderbilt University Selective inhibitors of prostaglandin endoperoxide synthase-2
US5929076A (en) * 1997-01-10 1999-07-27 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
US5783597A (en) * 1997-03-04 1998-07-21 Ortho Pharmaceutical Corporation 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use
US6004960A (en) * 1997-03-14 1999-12-21 Merck Frosst Canada, Inc. Pyridazinones as inhibitors of cyclooxygenase-2
US6071954A (en) * 1997-03-14 2000-06-06 Merk Frosst Canada, Inc. (methylsulfonyl)phenyl-2-(5H)-furanones with oxygen link as COX-2 inhibitors
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6046217A (en) * 1997-09-12 2000-04-04 Merck Frosst Canada & Co. 2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2
US6040450A (en) * 1997-09-25 2000-03-21 Merck & Co., Inc. Process for making diaryl pyridines useful as cox-2-inhibitors
FR2769311B1 (fr) * 1997-10-07 1999-12-24 Union Pharma Scient Appl Nouveaux derives 3,4-diarylthiazolin-2-one ou -2-thione, leurs procedes de preparation et leurs utilisations en therapeutique
US6133292A (en) * 1997-10-30 2000-10-17 Merck Frosst Canada & Co. Diaryl-5-alkyl-5-methyl-2-(5H)-furanones as selective cyclooxygenase-2-inhibitors
US6020347A (en) * 1997-11-18 2000-02-01 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
FR2771412B1 (fr) * 1997-11-26 2000-04-28 Adir Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EA002975B1 (ru) * 1998-04-24 2002-12-26 Мерк Энд Ко., Инк. Способ синтеза ингибиторов циклооксигеназы-2
US6077869A (en) * 1998-10-29 2000-06-20 Ortho-Mcneil Pharmaceutical, Inc. Aryl phenylhydrazides as selective COX-2 inhibitors for treatment of inflammation
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
US6077868A (en) * 1999-07-20 2000-06-20 Wisconsin Alumni Research Foundation Selective inhibition of cyclooxygenase-2
US6083969A (en) * 1999-10-20 2000-07-04 Ortho-Mcneil Pharaceutical, Inc. 1,3- and 2,3-diarylcycloalkano and cycloalkeno pyrazoles as selective inhibitors of cyclooxygenase-2 and antiinflammatory agents
AU2298301A (en) * 1999-10-20 2001-05-08 Board Of Trustees Of Southern Illinois University, The Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators
DE60016191T2 (de) * 1999-12-08 2005-12-22 Pharmacia Corp., Chicago Cyclooxygenase-2 hemmer enthaltende zusammensetzungen mit schnellem wirkungseintritt
EP1274425A1 (en) * 2000-04-18 2003-01-15 Pharmacia Corporation Rapid-onset formulation of a selective cyclooxigenase-2 inhibitor
US20020077328A1 (en) * 2000-07-13 2002-06-20 Fred Hassan Selective cyclooxygenase-2 inhibitors and vasomodulator compounds for generalized pain and headache pain
GB0617119D0 (en) * 2006-08-31 2006-10-11 Renovo Ltd Method of prognosis

Also Published As

Publication number Publication date
CN1287768C (zh) 2006-12-06
US20090081309A1 (en) 2009-03-26
PL366382A1 (en) 2005-01-24
EA200400148A1 (ru) 2004-08-26
PT1414409E (pt) 2007-03-30
DE60218175T2 (de) 2007-11-22
MXPA04001109A (es) 2005-02-17
CY1106548T1 (el) 2012-01-25
CA2454173A1 (en) 2003-02-20
CO5560559A2 (es) 2005-09-30
IL159551A0 (en) 2004-06-01
UA80682C2 (en) 2007-10-25
ATE353627T1 (de) 2007-03-15
EA007901B1 (ru) 2007-02-27
AP1817A (en) 2008-01-07
NZ530844A (en) 2005-11-25
GEP20074027B (en) 2007-02-12
CN1549704A (zh) 2004-11-24
DK1414409T3 (da) 2007-06-11
DE60218175D1 (de) 2007-03-29
ZA200400639B (en) 2005-04-08
MY135119A (en) 2008-02-29
HRP20040118A2 (en) 2004-06-30
TNSN04023A1 (fr) 2006-06-01
OA12646A (en) 2006-06-16
BR0211736A (pt) 2004-09-28
US20030108575A1 (en) 2003-06-12
WO2003013473A1 (en) 2003-02-20
EP1414409A1 (en) 2004-05-06
IS7126A (is) 2004-01-26
MA27054A1 (fr) 2004-12-20
YU7404A (sh) 2006-08-17
JP2005500363A (ja) 2005-01-06
ES2280560T3 (es) 2007-09-16
EP1414409B1 (en) 2007-02-14
KR20040025740A (ko) 2004-03-25
AP2004002969A0 (en) 2004-03-31
HK1069542A1 (en) 2005-05-27
SI1414409T1 (sl) 2007-06-30

Similar Documents

Publication Publication Date Title
ECSP044974A (es) Formulación de suspensión oral estabilizada
PA8509001A1 (es) Forma de dosificacion de farmacos accionada por un hidrogel
HRP20060240T3 (en) Intranasal formulation of rotigotine
EP1246608A4 (en) PHARMACEUTICAL PREPARATIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES WITH LOW WATER SOLUBILITY
NO20034149D0 (no) Legemidler inneholdende triazaspiro[5.5]undekanderivater som den aktive bestanddel
ATE450250T1 (de) Stabile zusammensetzung enhaltend partikel in einer gefrorenen wässrigen matrix
ES2190075T3 (es) Formulaciones farmaceuticas solidas que contienen una mezcla fisica de sulfoalquil-eter-ciclodextrina y un agente terapeutico.
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
ES2166829T3 (es) Composicion acuosa espumante.
PE20020307A1 (es) Forma de dosificacion de farmaco activada por hidrogel
AR038947A1 (es) Suspension oral de sabor agradable y metodo
AR017512A1 (es) Tabletas de metilcelulosa rapidamente desintegrables para administracion por via oral y procedimiento para prepararlas
HRP20010878B1 (en) Ziprasidone suspension
AR027554A1 (es) Nuevo sistema de adminstracion de farmacos autoemulsionante
CO5590911A2 (es) Composiciones farmaceuticas a base de derivados de azetidina
PT1189595E (pt) Composicoes oftalmicas sob a forma de geles aquosos
AR043536A1 (es) Composicion farmaceutica que comprende acido 5-metil-2-(2´-cloro-6´-fluoroanilino)fenilacetico
SE0001916D0 (sv) Novel formulation
BR0206960A (pt) Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose
CR7245A (es) Formulacion de suspension oral estabilizada
HRP20020332B1 (en) Oral solution containing galanthamine and a sweetening agent
NO20004816L (no) Ny farmasøytisk formulering
HRP20070081T5 (en) Nasal pharmaceutical composition of piribedil
ES2189639B1 (es) Composicion acuosa que contiene acido acetilsalicilico.
ITRM20000624A0 (it) Uso di derivati dell'acidocinnamico come agenti insetticidi.